Ardelyx's (ARDX) Outperform Rating Reiterated at Wedbush : v

Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a research note issued to investors on Friday, Benzinga reports. They currently have a $15.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 122.22% from the company’s previous close. […]

Related Keywords

United States , Piper Sandler , Leerink Partnrs , Davidp Rosenbaum , Sherbrooke Park Advisers , Ardelyx Inc , Citigroup , Securities Exchange Commission , Investment Consulting Inc , Jump Financial , Highmark Wealth Management , Newbridge Financial Services Group Inc , Get Free Report , Robert Ora Felsch , Exchange Commission , Mark Wealth Management , Park Advisers , Newbridge Financial Services Group , Ardelyx Daily ,